13
Aug
New Delhi, August 13 (Language) Rating agency Icra said on Monday that domestic active pharmaceutical ingredient producing companies are expected to see a growth of 7-8 percent in revenue by 2029.The rating agency expects revenues of its sample companies to grow at a CAGR of 7-8 percent between 2023 and 2029, from an estimated size of US$13-14 billion in 2023.It also estimates that there will be a marginal improvement in the operating profit margin (OPM) of its sample set of companies in FY2025. Domestic API industry players faced considerable volatility in earnings during FY 2021-2023 due to multiple constraints such…